PURPOSE: To analyze the effect of the oral antidiabetic drug metformin on PSA level, free-to-total PSA ratio (f/t-ratio), PCa incidence and grade as well as mortality in men participating in a population-based screening trial. METHODS: Data from 4,314 men aged 55-70 years from a population-based PSA-screening trial (ERSPC Aarau) were analyzed. Information on metformin exposure was obtained by a self-administered questionnaire. Serum PSA threshold at ≥3 ng/ml triggered prostate biopsy. Data on PCa incidence and mortality were obtained through registry linkages. RESULTS: Median follow-up time was 7.6 years. Mean age at baseline was 65.5 years (±SD 4.4). In all, n = 150 (3.5 %) men used metformin [metf+]. Mean baseline PSA levels were comparable between both groups ([metf+] 1.6 ng/ml ± 2.4 vs. [metf-] 1.8ug/l ± 2.2, p = 0.4) while f/t-ratio was slightly higher in metformin users ([metf+] 30.7 % ± 10.9 vs. [metf-] 27.3 % ± 10.9, p = 0.01). Overall, n = 372 (8.6 %) PCa cases were detected. Neither cumulative PCa incidence (n = 11; 7.3 % [metf+] vs. n = 361 8.7 % [metf-]; p = 0.5) nor d`Amico risk groups were significantly different between both groups. One man in each group (metf+ 0.7 % and metf- 0.02 %) died from PCa (p < 0.0001), respectively. All-cause mortality was significantly higher among met + compared to met- (adjusted OR 2.50, 95 %CI 1.59-3.82; p = 0.0001). CONCLUSION: No significant differences in PSA levels or PCa incidence and grade were observed. The slightly higher f/t-ratio did not result in lower PCa detection rate. Metformin users were at significantly higher risk of all-cause mortality. The relatively small number of men on metformin is a main limitation of the study.
PURPOSE: To analyze the effect of the oral antidiabetic drug metformin on PSA level, free-to-total PSA ratio (f/t-ratio), PCa incidence and grade as well as mortality in men participating in a population-based screening trial. METHODS: Data from 4,314 men aged 55-70 years from a population-based PSA-screening trial (ERSPC Aarau) were analyzed. Information on metformin exposure was obtained by a self-administered questionnaire. Serum PSA threshold at ≥3 ng/ml triggered prostate biopsy. Data on PCa incidence and mortality were obtained through registry linkages. RESULTS: Median follow-up time was 7.6 years. Mean age at baseline was 65.5 years (±SD 4.4). In all, n = 150 (3.5 %) men used metformin [metf+]. Mean baseline PSA levels were comparable between both groups ([metf+] 1.6 ng/ml ± 2.4 vs. [metf-] 1.8ug/l ± 2.2, p = 0.4) while f/t-ratio was slightly higher in metformin users ([metf+] 30.7 % ± 10.9 vs. [metf-] 27.3 % ± 10.9, p = 0.01). Overall, n = 372 (8.6 %) PCa cases were detected. Neither cumulative PCa incidence (n = 11; 7.3 % [metf+] vs. n = 361 8.7 % [metf-]; p = 0.5) nor d`Amico risk groups were significantly different between both groups. One man in each group (metf+ 0.7 % and metf- 0.02 %) died from PCa (p < 0.0001), respectively. All-cause mortality was significantly higher among met + compared to met- (adjusted OR 2.50, 95 %CI 1.59-3.82; p = 0.0001). CONCLUSION: No significant differences in PSA levels or PCa incidence and grade were observed. The slightly higher f/t-ratio did not result in lower PCa detection rate. Metformin users were at significantly higher risk of all-cause mortality. The relatively small number of men on metformin is a main limitation of the study.
Authors: Elizabeth A Atchison; Gloria Gridley; J Daniel Carreon; Michael F Leitzmann; Katherine A McGlynn Journal: Int J Cancer Date: 2011-02-01 Impact factor: 7.396
Authors: David Margel; David Urbach; Lorraine L Lipscombe; Chaim M Bell; Girish Kulkarni; Peter C Austin; Neil Fleshner Journal: J Natl Cancer Inst Date: 2013-07-13 Impact factor: 13.506
Authors: Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Alvaro Páez; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Sigrid Carlsson; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Paula M Kujala; Bert G Blijenberg; Ulf-Hakan Stenman; Andreas Huber; Kimmo Taari; Matti Hakama; Sue M Moss; Harry J de Koning; Anssi Auvinen Journal: N Engl J Med Date: 2012-03-15 Impact factor: 91.245
Authors: Thomas Höfner; Martin Zeier; Gencay Hatiboglu; Christian Eisen; Gita Schönberg; Boris Hadaschik; Dogu Teber; Stefan Duensing; Andreas Trumpp; Markus Hohenfellner; Sascha Pahernik Journal: World J Urol Date: 2013-12-27 Impact factor: 4.226
Authors: Tom Feng; Xizi Sun; Lauren E Howard; Adriana C Vidal; Alexis R Gaines; Daniel M Moreira; Ramiro Castro-Santamaria; Gerald L Andriole; Stephen J Freedland Journal: Cancer Prev Res (Phila) Date: 2015-09-09
Authors: Chen-Pin Wang; Donna M Lehman; Yui-Wing F Lam; John G Kuhn; Devalingam Mahalingam; Steven Weitman; Carlos Lorenzo; John R Downs; Elizabeth A Stuart; Javier Hernandez; Ian M Thompson; Amelie G Ramirez Journal: Cancer Prev Res (Phila) Date: 2016-03-29
Authors: Viranda H Jayalath; Christopher Ireland; Neil E Fleshner; Robert J Hamilton; David J A Jenkins Journal: Prostate Date: 2016-07-12 Impact factor: 4.104
Authors: Kerri Beckmann; Danielle Crawley; Tobias Nordström; Markus Aly; Henrik Olsson; Anna Lantz; Noor Binti Abd Jalal; Hans Garmo; Jan Adolfsson; Martin Eklund; Mieke Van Hemelrijck Journal: JAMA Netw Open Date: 2019-11-01
Authors: Pete T T Kinnunen; Teemu J Murtola; Kirsi Talala; Kimmo Taari; Teuvo L J Tammela; Anssi Auvinen Journal: BMC Cancer Date: 2017-08-29 Impact factor: 4.430